External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESH-CART 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Oct 9 / Roche
Watch Improving patient care in DLBCL across treatment lines
An expert panel will be exploring the role of emerging bispecific antibodies in the evolving diffuse large B-cell lymphoma (DLBCL) treatment landscape and considerations for their use and adoption in clinical practice. This session will have a strong focus on interactive knowledge exchange, allowing delegates the oppurtunity to participate in a live panel discussion and Q&A.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 9 / Roche
Watch Bispecific antibodies in DLBCL: present and future prospects
An expert panel will be exploring the role of emerging bispecific antibodies in the evolving diffuse large B-cell lymphoma (DLBCL) treatment landscape and considerations for their use and adoption in clinical practice. This session will have a strong focus on interactive knowledge exchange, allowing delegates the oppurtunity to participate in a live panel discussion and Q&A.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 9 / Roche
Watch Conversations and clinical insights
An expert panel will be exploring the role of emerging bispecific antibodies in the evolving diffuse large B-cell lymphoma (DLBCL) treatment landscape and considerations for their use and adoption in clinical practice. This session will have a strong focus on interactive knowledge exchange, allowing delegates the oppurtunity to participate in a live panel discussion and Q&A.
09:40 AM
Duration 5mins Berlin / Germany
Bispecific antibodies in DLBCL: present and future prospects
Glass B, Fox C, Umana P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar